Aeluma, Inc. 10-Q

Item 1. Financial Statements Aeluma, Inc. and Subsidiary Condensed Consolidated Balance Sheets ($ in thousands, except per share data) March 31, 2026 (unaudited) June 30, 2025 Assets Current assets: Cash and cash equivalents $ 37,780 $ 3,628 Certificate of deposit - 12,112 Accounts receivable 1,062 962 Prepaids and other current assets 1,332 633 Total current assets 40,174 17,335 Property and equipment: Equipment 2,131 1,692 Leasehold improvements 547 547 Accumulated depreciation ( 1,344 ) ( 1,021 ) Property and equipment, net 1,334 1,218 Right of use asset - operating 987 836 Other assets 22 17 Total assets $ 42,517 $ 19,406 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 973 $ 361 Accrued expenses and other current liabilities 370 206 Lease liability – operating, current portion 196 138 Total current liabilities 1,539 705 Lease liability - operating, long-term portion 893 803 Total liabilities 2,432 1,508 Commitments and contingencies - - Stockholders’ equity: Preferred stock, $ 0.0001 par value: 10,000,000 authorized, and none issued and outstanding at March 31, 2026 and June 30, 2025 - - Common stock, $ 0.0001 par value: 50,000,000 shares authorized, and 18,113,554 and 15,864,360 shares issued and outstanding at March 31, 2026 and June 30, 2025, respectively 2 2 Additional paid-in capital 61,875 34,542 Accumulated deficit ( 21,792 ) ( 16,646 ) Total stockholders’ equity 40,085 17,898 Total liabilities and stockholders’ equity $ 42,517 $ 19,406 The accompanying notes are an integral part of these financial statements. 1 Aeluma, Inc. and Subsidiary Condensed Consolidated Statements of Operations (unaudited) ($ in thousands, except per share data) Three Months Ended March 31, Nine Months Ended March 31, 2026 2025 2026 2025 Revenue $ 1,222 $ 1,255 $ 3,879 $ 3,348 Operating expenses: Cost of revenue 836 311 2,456 1,105 Research and development 882 471 2,394 1,130 General and administrative 1,629 1,305 4,843 2,287 Total operating expenses 3,347 2,087 9,693 4,522 Loss from operations ( 2,125 ) ( 832 ) ( 5,814 ) ( 1,174 ) Other income (expense): Interest income 325 3 668 3 Amortization of discount on convertible notes - ( 287 ) - ( 715 ) Changes in fair value of derivative liabilities - 2,577 - ( 278 ) Total other income (expense), net 325 2,293 668 ( 990 ) Income (loss) before income tax expense ( 1,800 ) 1,461 ( 5,146 ) ( 2,164 ) Income tax expense - - - - Net income (loss) $ ( 1,800 ) $ 1,461 $ ( 5,146 ) $ ( 2,164 ) Net income (loss) per share: Basic $ ( 0.10 ) $ 0.12 $ ( 0.30 ) $ ( 0.18 ) Diluted $ ( 0.10 ) $ 0.11 $ ( 0.30 ) $ ( 0.18 ) Weighted average common shares outstanding: Basic 18,061,402 12,472,061 17,354,370 12,286,284 Diluted 18,061,402 13,206,919 17,354,370 12,286,284 The accompanying notes are an integral part of these financial statements. 2 Aeluma, Inc. and Subsidiary Condensed Consolidated Statement of Stockholders’ Equity (unaudited) ($ in thousands) Three Months Ended March 31, 2026 and 2025 Common Stock Additional Paid-in Accumulated Total Stockholders’ Shares Amount Capital Deficit Equity Balance, January 1, 2026 18,002,727 $ 2 $ 60,793 $ ( 19,992 ) $ 40,803 Restricted stock units vested 21,871 - - - - Restricted stock units surrendered due to net share settlement to satisfy employee tax liability ( 3,666 ) - ( 56 ) - ( 56 ) Stock options exercised 85,617 - 39 - 39 Stock warrants exercised 7,005 - - - - Stock-based compensation - - 1,099 - 1,099 Net loss - - - ( 1,800 ) ( 1,800 ) Balance, March 31, 2026 18,113,554 $ 2 $ 61,875 $ ( 21,792 ) $ 40,085 Common Stock Additional Paid-in Accumulated Total Stockholders’ Shares Amount Capital Deficit Equity Balance, January 1, 2025 12,242,481 $ 1 $ 16,215 $ ( 17,249 ) $ ( 1,033 ) Issuance of common stock, net of offering costs 2,628,571 1 12,587 - 12,588 Conversion of convertible notes 898,573 - 1,667 - 1,667 Conversion of derivative liabilities - - 2,471 - 2,471 Stock options exercised 25,842 - 10 - 10 Stock-based compensation - - 833 - 833 Net income - - - 1,461 1,461 Balance, March 31, 2025 15,795,467 $ 2 $ 33,783 $ ( 15,788 ) $ 17,997 Nine Months Ended March 31, 2026 and 2025 Common Stock Additional paid-in Accumulated Total Stockholders’ Shares Amount capital Deficit Equity Balance, July 1, 2025 15,864,360 $ 2 $ 34,542 $ ( 16,646 ) $ 17,898 Issuance of common stock, net of offering costs 1,955,000 - 23,385 - 23,385 Restricted stock units vested 29,218 - - - - Restricted stock units surrendered due to net share settlement to satisfy employee tax liability ( 3,666 ) - ( 56 ) - ( 56 ) Stock options exercised 129,098 - 103 - 103 Stock warrants exercised 139,544 - 690 - 690 Stock-based compensation - - 3,211 - 3,211 Net loss - - - ( 5,146 ) ( 5,146 ) Balance, March 31, 2026 18,113,554 $ 2 $ 61,875 $ ( 21,792 ) $ 40,085 Common Stock Additional paid-in Accumulated Total Stockholders’ Shares Amount capital Deficit Equity Balance, July 1, 2024 12,178,424 $ 1 $ 15,899 $ ( 13,624 ) $ 2,276 Issuance of common stock, net of offering costs 2,628,571 1 12,587 - 12,588 Conversion of convertible notes 898,573 - 1,667 - 1,667 Conversion of derivative liabilities - - 2,471 - 2,471 Stock options exercised 88,169 - 10 - 10 Stock warrants exercised 1,730 - - - - Stock-based compensation - - 1,149 - 1,149 Net loss - - - ( 2,164 ) ( 2,164 ) Balance, March 31, 2025 15,795,467 $ 2 $ 33,783 $ ( 15,788 ) $ 17,997 The accompanying notes are an integral part of these financial statements. 3 Aeluma, Inc. and Subsidiary Condensed Consolidated Statements of Cash Flows (unaudited) ($ in thousands) Nine Months Ended March 31, 2026 2025 Operating activities: Net loss $ ( 5,146 ) $ ( 2,164 ) Adjustments to reconcile net loss to net cash used in operating activities: Amortization of deferred compensation - 17 Stock-based compensation expense 3,211 1,149 Depreciation and amortization expense 325 307 Amortization of discount on convertible notes - 715 Changes in fair value of derivative liabilities - 278 Changes in operating assets and liabilities: Accounts receivable ( 100 ) ( 1,083 ) Prepaids and other current assets ( 699 ) ( 192 ) Other assets ( 7 ) - Accounts payable 612 ( 144 ) Accrued expenses and other current liabilities 161 34 Net cash used in operating activities ( 1,643 ) ( 1,083 ) Investing activities: Purchase of equipment ( 439 ) ( 85 ) Net cash used in investing activities ( 439 ) ( 85 ) Financing activities: Proceeds from stock option exercise 103 10 Proceeds from stock warrant exercise 690 - Proceeds from convertible notes issuance - 3,145 Proceeds from public offering, net of offering costs 23,385 12,587 Payment for taxes related to net share settlement of restricted stock units ( 56 ) - Net cash provided by financing activities 24,122 15,742 Net change in cash and cash equivalents, and certificate of deposit 22,040 14,574 Cash and cash equivalents, and certificate of deposit, beginning of period 15,740 1,291 Cash and cash equivalents, and certificate of deposit, end of period $ 37,780 $ 15,865 Supplemental non-cash disclosures: Right of use asset - operating obtained in exchange for lease liability -operating $ 274 $ - Conversion of convertible notes to stockholders’ equity - 1,667 Conversion of derivative liabilities to stockholders’ equity - 2,471 The accompanying notes are an integral part of these financial statements. 4 Aeluma, Inc. and Subsidiary Notes to Condensed Consolidated Financial Statements (unaudited) Note 1 – The Company and Basis of Presentation Throughout these notes, “the Company,” “Aeluma,” “we,” “us”, “its” and “our” refer to Aeluma, Inc. and our wholly owned subsidiary Aeluma Operating Co. (“Subsidiary”). Aeluma develops novel optoelectronic and electronic devices for sensing, communication, and computing applications. Aeluma has pioneered a technique to produce semiconductor materials and chips using high-performance compound semiconductors on large-diameter substrates commonly used to manufacture mass-market microelectronics. This enables cost-effective manufacturing of high-performance photodetectors and photodetector arrays for imaging applications in mobile devices and other applications. Aeluma’s technology is broadly applicable across mobile, automotive, artificial intelligence (“AI”), defense & aerospace, communication, augmented reality (“AR”), virtual reality (“VR”), high-performance computing, and quantum computing. Aeluma is based in Goleta, California, where the Company operates in a 9,000 sq. ft. facility with a state-of-the-art research and development (“R&D”) and manufacturing cleanroom and access to world-class rapid prototyping capabilities. The facility houses unique equipment for scalable manufacturing. In September 2025, the Company added a second facility with 2,400 sq. ft. of office and meeting space, also in Goleta, California. Aeluma also partners with production-scale fabrication foundries and packaging companies. Aeluma maintains extensive patent protection and trade secrets related to its materials, manufacturing technology, and applications. The accompanying condensed consolidated financial statements have been presented in accordance with U.S. generally accepted accounting principles (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who is responsible for the Company’s integrity and objectivity. This Quarterly Report on Form 10-Q for the period ended March 31, 2026, should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended June 30, 2025. The accompanying consolidated financial statements and footnotes have been condensed and therefore do not contain all disclosures required by GAAP. The interim financial data are unaudited; however, in the opinion of Aeluma, the interim data include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Results for interim periods are not necessarily indicative of those to be expected for the full year. Cash and Cash Equivalents The Company considers cash in banks, deposits in transit, and highly liquid investments with original maturity of three months or less to be cash and cash equivalents. As of March 31, 2026, cash and cash equivalents consisted of cash on deposit and an investment in money market funds. The Company’s investment in money market funds is classified within Level 1 of the fair value hierarchy because it is valued using quoted market prices in active markets. The fund invests 100 % of its assets in short-term U.S. Treasury obligations and has no minimum holding periods or redemption gates. Revenue Recognition The Company follows a five-step approach for recognizing revenue: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when, or as, the entity satisfies a performance obligation. Revenue is recognized when control of the promised goods or services is transferred to the customer. For performance obligations that are satisfied at a single point in time, the Company recognizes revenue at the point when control transfers, which is typically upon delivery, customer acceptance, or another specified milestone defined in the contract. For performance obligations satisfied over time, revenue is recognized as progress is made toward completion, using a measure that best depicts the transfer of control to the customer. Sales and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expenses. The Company does not have any significant financing components associated with its revenue contracts, as payment is received within one year. The Company currently draws revenue from two primary sources: ● Commercial product and service contracts: Revenue is currently generated from multiple customers for R&D-related services and small-volume orders. ● Government contracts: Revenue is principally generated from R&D contracts with agencies of the U.S. government or with prime contractors. These contracts may include cost-reimbursement or fixed-price terms. 5 The Company capitalizes certain incremental costs incurred to obtain or fulfill a contract when such costs are expected to be recoverable. Prepaid costs, such as advance payments to vendors or subcontractors directly related to a customer contract, are recorded as assets and subsequently expensed consistent with the transfer of goods or services to the customer. Government contracts include both cost-reimbursement and fixed-price contracts. Cost-reimbursement contracts provide for the reimbursement of allowable costs plus the payment of a fee. These contracts fall into four basic types: (i) cost-sharing contract under which government reimburses only a portion of the incurred costs, (ii) cost plus fixed fee contracts which provide for the payment of a fixed fee irrespective of the final cost of performance, (iii) cost plus incentive fee contracts which provide for increases or decreases in the fee, within specified limits, based upon actual results as compared to contractual targets relating to such factors as cost, performance and delivery schedule, and (iv) cost plus award fee contracts which provide for the payment of an award fee determined at the discretion of the customer based upon the performance of the contractor against pre-established criteria. Under cost-reimbursement type contracts, the contractor is reimbursed periodically for allowable costs and is paid a portion of the fee based on contract progress. Fixed-price contracts establish a set price for goods or services, which may be firm or adjustable under specific conditions. Adjustable fixed-price contracts can include elements such as ceiling or target prices, which are only subject to change through contract clauses that allow for equitable adjustments. Firm-fixed-price contracts do not permit any price changes based on the contractor’s actual costs, placing full financial risk and responsibility on the contractor. In contrast, fixed-price contracts with economic price adjustments allow for price changes, either increases or decreases, based on predefined events or conditions. For the three and nine months ended March 31, 2026, the Company was awarded government contracts of $ 2.3 million and $ 2.5 million, respectively, for the provision of services and delivery of materials. The awards are either firm-fixed-price contracts, where payments are made upon completion of specified performance milestones, or cost-reimbursement contracts, where allowable costs are reimbursed with an additional fee. For the three and nine months ended March 31, 2025, the Company was awarded two government contracts of $ 11.9 million for providing services and delivering materials. The awards are firm-fixed-price contracts. As of March 31, 2026, total remaining performance obligations under all obligated government contracts amounted to $ 8.9 million. Stock-Based Compensation The Company accounts for stock-based compensation arrangements in accordance with guidance issued by the Financial Accounting Standards Board (“FASB”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model for stock options. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and rely on subjective variables. For employees and directors, the expected life was calculated based on the simplified method as described by the U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company’s estimate of expected volatility was based on the volatility of peers. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options. The Company accounts for forfeitures upon occurrence. The Company estimates the fair value of restricted stock units (“RSUs”) on the date of grant based on the fair market value of the Company’s common stock. The value of the portion of the award that is ultimately expected to vest is recognized as stock-based compensation expense over the requisite service periods in the Company’s consolidated statements of operations. Because RSUs do not include exercise features, the valuation of these awards does not require the use of an option-pricing model or assumptions related to expected volatility, expected term, or risk-free interest rates. The Company accounts for forfeitures upon occurrence. 6 Income (Loss) Per Share Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the sum of the weighted average number of common shares outstanding plus potential dilutive common shares outstanding during the period. Potential dilutive securities, comprised of shares underlying stock options, restricted stock units, and warrants, are not reflected in diluted loss per share because such shares are anti–dilutive. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. For the three and nine months ended March 31, 2026, 1,883,328 shares underlying stock options, 274,493 shares underlying RSUs and 394,408 shares underlying warrants were excluded from the calculation of diluted income per share as their inclusion would have been anti-dilutive. Concentration of Risk The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company’s accounts are insured by the FDIC up to federally insured limits. The Company manages its credit risk associated with exposure to its direct customers on outstanding accounts receivable through the application of credit approvals and other monitoring procedures. The Company closely monitors the aging of accounts receivable from its direct customers. Significant customers are those that represent 10% or more of revenue or accounts receivable. For the three months ended March 31, 2026, 60 % and 16 % of our revenue was derived from two customers and, for the three months ended March 31, 2025, 90 % of our revenue was derived from one customer. For the nine months ended March 31, 2026, 68 % and 15 % of our revenue was derived from two customers and, for the nine months ended March 31, 2025, 70 % of our revenue was derived from one customer. As of March 31, 2026, 76 % and 17 % of accounts receivables were attributable to two customers and, as of June 30, 2025, 100 % of accounts receivable were attributable to one customer. All customers are government agencies. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported consolidated financial statements Recent Accounting Pronouncements under Evaluation In July 2025, the FASB issued Accounting Standards Update (“ASU”) 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets . This ASU provides a practical expedient to assume that conditions as of the balance sheet date remain unchanged over the life of the asset when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606. This guidance is effective for annual reporting periods beginning after December 15, 2025, and for interim periods within those annual reporting periods, with early adoption permitted. The amendments in ASU 2025-05 should be applied prospectively. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, however the adoption is not expected to have a material impact on the consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures . This ASU amends the disclosure requirements for income taxes, including the requirement for further disaggregation of the income tax rate reconciliation and income taxes paid disclosures. The amendments in this guidance must be applied prospectively, with the option to apply retrospectively. This guidance is effective for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, however the adoption is not expected to have a significant impact on the consolidated financial statements. In November 2024, the FASB issued ASU. 2024-03, Disaggregation of Income Statement Expenses (DISE) . The ASU requires additional disclosure regarding specific types of expenses included in the income statement. This guidance applies to all public business entities and is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, however the adoption is not expected to have a significant impact on the consolidated financial statements. 7 Note 2 – Convertible Notes During August 2024, we issued convertible promissory notes in the aggregate principal amount of $ 3.1 million to 10 accredited investors, pursuant to a private note financing. The Notes were set to mature in June 2026 and did not carry any interest. The Notes were convertible into shares of the Company’s common stock par value $ 0.0001 per share (the “Common Stock”) upon the occurrence of certain events, (i.e., qualified financing resulting in at least $ 5.0 million to the Company, if the Common Stock was uplisted to a national securities exchange or if neither of those such events occurred prior to the maturity date, (together with Sale of the Company (as hereinafter defined), a “Conversion Event”)). On March 25, 2025, the Company determined that a Conversion Event had occurred pursuant to the terms of the Notes. As a result, certain holders elected to convert their Notes at the applicable Ceiling Price of $ 3.50 per share, resulting in the issuance of an aggregate of 898,573 shares of Common Stock in exchange for $ 3.1 million in outstanding principal under the Notes. Following the conversion, the Company has no further obligations under the converted Notes. The shares issued upon conversion are subject to piggyback registration rights previously granted to the investors. See Public Offerings of Common Stock in Note 3 – Stockholders’ Equity Beginning with the quarter ended March 31, 2025, the carrying amount of convertible notes, totaling $ 1.7 million, including unamortized debt discount of $ 1.5 million, was reclassed to equity. For the three and nine months ended March 31, 2025, the Company recorded amortization of discount on convertible notes of $ 287 thousand and $ 715 thousand, respectively. Note 3 – Stockholders’ Equity Authorized Shares The Company’s Articles of Incorporation authorize the issuance of two classes of shares of capital stock. The total number of shares that this corporation is authorized to issue is 50,000,000 shares of $ 0.0001 par value common stock and 10,000,000 of $ 0.0001 par value preferred stock. No preferred shares were issued or outstanding as of March 31, 2026. Registration Rights Agreement The Company is party to a registration rights agreement pursuant to which it has filed a registration statement on Form S-1 with the SEC, which was declared effective on March 26, 2025. The agreement provides for certain liquidated damages upon the occurrence of a “Registration Event,” which is defined as the occurrence of any of the following events: (a) the registration statement ceases for any reason to remain effective or the Holders of Registrable Securities covered thereby are otherwise not permitted to utilize the prospectus therein to resell the Registrable Securities covered thereby, except for Blackout Periods permitted by the registration rights agreement; or (b) following the listing or inclusion for quotation on an Approved Market, the Registrable Securities, if issued and outstanding, are not listed or included for quotation on an Approved Market, or trading of the Common Stock is suspended or halted on the Approved Market, which at the time constitutes the principal markets for the Common Stock, for more than three (3) full, consecutive Trading Days (other than as a result of (A) actions or inactions of parties other than the Company or its affiliates or of the Approved Market not reasonably in the control of the Company, or (B) suspension or halt of substantially all trading in equity securities (including the Common Stock) on the Approved Market). The maximum amount of liquidated damages that may be paid by the Company shall be an amount equal to eight percent ( 8 %) of the shares covered by the registration rights agreement. The registration statement initially covered the sale of 11,010,002 shares. The Company currently expects to satisfy all of its obligations under the Registration Agreement and does not expect to pay any damages pursuant to this agreement; therefore, no liability has been recorded. Public Offerings of Common Stock In March 2025, the Company sold an aggregate of 2,628,571 shares of its common stock in an underwritten public offering for gross proceeds of $ 13.8 million, resulting in net proceeds of $ 12.6 million after underwriting discounts, commissions, and offering expenses. The Company issued to the underwriter warrants to purchase up to 131,427 shares which are exercisable for a per share price of $ 6.04 through March 2035. See Note 6 - Warrants 8 On September 19, 2025, the Company sold 1,955,000 shares of its common stock in an underwritten public offering for gross proceeds of $ 25.4 million, resulting in net proceeds of $ 23.4 million after underwriting discounts, commission, and offering expenses. On March 20, 2026, we entered into a sales agreement, pursuant to which we may sell shares of our common stock having an aggregate offering price of up to $ 50 million, through an “at-the-market” offering program. As of March 31, 2026, no sales of our common stock were transacted under this agreement. We are not obligated to sell, and the agents are not obligated to buy or sell, any shares under the agreement. Any shares will be offered and sold under the agreement will be pursuant to the Company’s effective shelf registration statement on Form S-3. Note 4 – Stock-Based Compensation Restricted Stock Awards Restricted Stock Awards (“RSAs”) are grants of shares of our common stock that vest in accordance with terms and conditions established by the Company’s Board of Directors. Recipients of RSAs generally will have voting and dividend rights with respect to such shares upon grant without regard to vesting, unless the RSA agreement provides otherwise. Shares of restricted stock that do not vest are subject to forfeiture. The Company has entered into various consulting agreements that involved the issuance of common stock in exchange for future services. These agreements included time-based vesting provisions and repurchase rights tied to service terms. In connection with these agreements, the Company recorded deferred compensation for the fair value of the shares in excess of the amounts paid. The deferred compensation was recognized as consulting expense in the condensed consolidated statements of operations over the applicable service periods. For the three and nine months ended March 31, 2025, $ 3 thousand and $ 17 thousand, respectively, were recognized as consulting expense in the condensed consolidated statements of operations. All related shares had vested and the associated expense was fully amortized as of March 31, 2026. Accordingly, as of March 31, 2026, there was no deferred compensation remaining in the condensed consolidated balance sheets. Restricted Stock Units RSUs are rights to acquire shares of our common stock that vest and settle in accordance with terms and conditions established by our 2021 Equity Incentive Plan (the “2021 Plan”) and any forms of agreement approved by the administrator of the 2021 Plan. During the three months ended September 30, 2025, the Company granted RSUs to employees representing rights to acquire up to 76,403 shares of common stock. Of those RSUs, 2,903 were fully vested on the date of grant and settled into the same number of shares of common stock. The remaining RSUs are scheduled to vest with respect to 25 % of the shares on the first anniversary of the grant recipient’s start date and the remaining 75 % in equal quarterly installments over the following 12 quarters. Each vesting installment is subject to the recipient’s continued service with the Company through the applicable vesting date. During the three months ended December 31, 2025, the Company granted RSUs to employees, consultants and members of the Company’s board of directors representing rights to acquire up to 87,458 shares of common stock. The RSUs are scheduled to vest over varying periods of up to four years. Each vesting installment is subject to the recipient’s continued service with the Company through the applicable vesting date. 9 During the three months ended March 31, 2026, the Company granted RSUs to employees representing rights to acquire up to 139,850 shares of common stock. The RSUs are scheduled to vest over varying periods of up to four years. Each vesting installment is subject to the recipient’s continued service with the Company through the applicable vesting date. March 31, 2026 Three Months Ended Nine Months Ended Number of Shares Weighted Average Grant Date Fair Value per Share Number of Shares Weighted Average Grant Date Fair Value per Share Beginning balance 156,292 $ 18.03 - $ - Granted 139,850 15.44 303,711 16.80 Vested ( 21,649 ) 16.12 ( 29,218 ) 16.22 Canceled - - - - Ending balance 274,493 $ 16.87 274,493 $ 16.87 Stock Options For the three months ended September 30, 2025, the Company granted to employees and a member of the Company’s board of directors options to purchase up to 157,906 shares of common stock. The stock options expire on the tenth anniversary of their dates of grant, have exercise prices ranging from $ 16.37 to $ 20.82 , and vest in one month to forty-eight months. The right to exercise vested options is contingent upon the optionee’s continued service with the Company through each applicable vesting date. For the three months ended December 31, 2025, the Company granted to employees and a consultant options to purchase up to 77,000 shares of common stock. The stock options expire on the tenth anniversary of their dates of grant, have exercise prices ranging from $ 14.71 to $ 16.31 , and vest in one month to forty-eight months. The right to exercise vested options is contingent upon the optionee’s continued service with the Company through each applicable vesting date. For the three months ended March 31, 2026, the Company granted to employees options to purchase up to 262,800 shares of common stock. The stock options expire on the tenth anniversary of their dates of grant, have exercise prices ranging from $ 12.20 to $ 21.60 , and vest over varying periods of up to five years. The right to exercise vested options is contingent upon the optionee’s continued service with the Company through each applicable vesting date. The Company estimates the fair value of each option granted using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options for the period presented: Nine Months Ended March 31, 2026 2025 Weighted-average fair value $ 14.26 $ 5.66 Expected volatility 101.4 % - 119.2 % 113.9 % - 138.3 % Expected term 5.0 years – 7.4 years 0.9 years - 6.0 years Dividend yield 0.00 % 0.00 % Risk-free interest rate 3.69 % - 4.07 % 3.87 % - 4.60 % 10 The following is a schedule summarizing stock option activities for the periods presented ($ in thousands, except per share data): Three Months Ended Number of Options Weighted Average Exercise Price Aggregate Intrinsic Value (1) Outstanding at January 1, 2026 1,724,069 $ 7.22 $ 17,688 Granted 262,800 15.34 Exercised ( 102,500 ) 2.99 Canceled ( 1,041 ) 2.00 Outstanding at March 31, 2026 1,883,328 $ 8.59 $ 10,606 Exercisable at March 31, 2026 1,020,637 $ 4.75 $ 8,569 Number of Options Weighted Average Exercise Price Aggregate Intrinsic Value (1) Outstanding at January 1, 2025 954,821 $ 2.51 $ 4,908 Granted 451,354 7.81 Exercised ( 37,291 ) 2.35 Canceled ( 4,688 ) 2.00 Outstanding at March 31, 2025 1,364,196 $ 4.27 $ 4,167 Exercisable at March 31, 2025 768,114 $ 3.11 $ 3,090 (1) Represents the excess of the fair value on the last day of the period (which was $ 13.09 and $ 7.21 as of March 31, 2026 and 2025, respectively) over the exercise price, multiplied by the number of options. Nine Months Ended Number of Options Weighted Average Exercise Price Aggregate Intrinsic Value (1) Outstanding at July 1, 2025 1,570,675 $ 5.33 $ 17,410 Granted 497,706 16.94 Exercised ( 149,436 ) 2.84 Canceled ( 35,617 ) 5.67 Outstanding at March 31, 2026 1,883,328 $ 8.59 $ 10,606 Exercisable at March 31, 2026 1,020,637 $ 4.75 $ 8,569 Number of Options Weighted Average Exercise Price Aggregate Intrinsic Value (1) Outstanding at July 1, 2024 1,068,446 $ 2.41 $ 1,258 Granted 517,354 7.21 Exercised ( 192,957 ) 2.16 Canceled ( 28,647 ) 2.33 Outstanding at March 31, 2025 1,364,196 $ 4.27 $ 4,167 Exercisable at March 31, 2025 768,114 $ 3.11 $ 3,090 (1) Represents the excess of the fair value on the last day of the period (which was $ 13.09 and $ 7.21 as of March 31, 2026 and 2025, respectively) over the exercise price, multiplied by the number of options. 11 The Company granted performance-based equity awards that vest upon achievement of specified sales targets over a defined performance period. Stock-based compensation expense is recognized only when achievement of the sales targets is considered probable. The Company reassesses this probability at each reporting date and adjusts expense accordingly. If the targets are not deemed probable, no expense is recognized and any previously recognized amounts are reversed. For both the three and nine months ended March 31, 2026, the Company recognized $ 44 thousand of expense related to these awards. As of March 31, 2026, remaining unrecognized compensation cost for these grants was $ 1.2 million, to be recognized over 4.8 years , subject to achieving the sales targets. For the three months ended March 31, 2026 and 2025, stock-based compensation expenses for stock options and RSUs were $ 1.1 million and $ 832 thousand, respectively. For the nine months ended March 31, 2026 and 2025, stock-based compensation expenses for stock options and RSUs were $ 3.2 million and $ 1.1 million, respectively. Unrecognized stock-based compensation expense was $ 13.0 million, and the average expected recognition period was 2.0 years as of March 31, 2026. Note 5 – Operating Lease Lease expense for operating leases is recognized on a straight-line basis over the term of the lease. Right of Use (“ROU”) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. The Company includes lease extension and termination options in the lease term when it is reasonably certain, based on consideration of relevant economic factors, that such options will be exercised. The Company entered into an amendment dated November 20, 2025, which modified its existing lease originally executed on February 22, 2021, for a facility in Goleta, California, reflecting the exercise of one of the two original sixty-month extension options and extending the lease term for an additional five years from April 1, 2026 through March 31, 2031. The Company has one option to extend the term for an additional five years remaining under the lease . The Company is party to a 5 -year operating lease for an office in Goleta, California through September 21, 2030, with total lease payments of $ 303 thousand. The Company recorded the net present value of $ 274 thousand for both the ROU asset and lease liability on September 5, 2025. The following table presents maturities of operating lease liabilities on an undiscounted basis as of March 31, 2026 ($ in thousands): Years ending June 30, 2026 $ 59 2027 237 2028 243 2029 248 2030 253 Thereafter 162 Total 1,202 Less imputed interest ( 113 ) Total lease liability - operating 1,089 Less: lease liability - operating, current portion 196 Lease liability - operating, long-term portion $ 893 12 The weighted average remaining lease term and the discount rate for the lease at March 31, 2026 are 4.8 years and 3.95 %, respectively. The total lease expenses were $ 57 thousand and $ 48 thousand for the three months ended March 31, 2026 and 2025, respectively. The total lease expenses were $ 161 thousand and $ 131 thousand for the nine months ended March 31, 2026 and 2025, respectively. The variable costs for common area operating expenses and electricity were $ 87 thousand and $ 31 thousand for the three months ended March 31, 2026 and 2025, respectively. The variable costs for common area operating expenses and electricity were $ 245 thousand and $ 231 thousand for the nine months ended March 31, 2026 and 2025, respectively. Note 6 – Warrants All of our outstanding warrants to purchase common stock are exercisable at any time prior to their expiration dates and include a provision that allows for cashless exercise at the time of exercise. Under the cashless exercise provision, the holder may elect to receive a reduced number of shares of common stock determined according to a formula based on the fair market value of the Company’s common stock at the time of exercise, rather than paying the exercise price in cash. During the three months ended March 31, 2026, warrants to purchase 8,000 shares were exercised, resulting in the issuance of 7,005 shares of common stock. During the nine months ended March 31, 2026, warrants to purchase 148,480 shares were exercised, resulting in the issuance of 139,544 shares of common stock. The following warrants to purchase common stock were outstanding as of March 31, 2026: Number of Shares Exercise Price Expiration Date 266,255 $ 2.00 June 22, 2026 37,058 2.00 June 28, 2026 11,393 2.00 July 1, 2026 26,762 3.00 December 22, 2027 4,542 3.00 January 10, 2028 6,660 3.00 March 31, 2028 41,738 3.00 March 10, 2028 394,408 13